newsfilter
← Latest News
Business Wire·

Tempus Announces the Upcoming Clinical Availability of Its First Whole-Genome Sequencing Assay, xH

Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the upcoming clinical availability of xH, a next-generation sequencing (NGS) test that uses a